Clinical Trial Update: A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa [Phase 3]

View source ↗

Summary

Phase 3 long-term study evaluating bimekizumab in participants with moderate to severe hidradenitis suppurativa is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Bimekizumab (bimekizumab)

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Hidradenitis Suppurativa | Phase 3 | Status: ACTIVE_NOT_RECRUITING